In this webinar, Beth Belluscio, MD, PhD, Pfizer Global Clinical Lead for Rare Neurological Disorders, discusses the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Dr. Belluscio answers questions from the Duchenne community about the study including aspects of the design and the criteria for enrollment, followed by a Q&A session about the study facilitated by CureDuchenne. Pfizer answers as many questions as possible to ensure that the Duchenne community is well-informed. Please know that, in this forum, Pfizer
will is not be able to answer questions about the ongoing Phase 1b study.
Beth Belluscio, MD, PhD | Pfizer Global Clinical Lead for Rare Neurological Disorders
For more information regarding the Pfizer Phase III clinical trial, please click here
You’ll be prompted to enter your name and email address to view the recording.